Amoydx

17 /Aug

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Vienna – Aug. 7th, 2022. – A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping).

17 /Aug

Amoy Diagnostics and Roche Jointly Announce Strategic Partnership

The 2nd Roche Pan-Tumor Precision Medicine Innovation Forum was officially held at the Shanghai Roche Campus, where participants had discussions on recent progresses in this field.

09 /Aug

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

TOKYO and XIAMEN, August 9, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) had been approved by t

08 /Jul

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

AmoyDx is excited to join the IASLC 2022 World Conference on Lung Cancer (Booth# 307), held in person with virtual elements in Vienna, Austria from August 6 – 9, 2022.

17 /Aug AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation
17 /Aug Amoy Diagnostics and Roche Jointly Announce Strategic Partnership
09 /Aug MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan
08 /Jul Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

more 

05 /May

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

AmoyDx will be attending the American Society of Clinical Oncology 2022 annual meeting (Booth 2052), held in person and virtually in Chicago, IL from June 3-7. We look forward to seeing you in Chicago.

20 /Apr

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx^{^®} Pan Lung Cancer PCR Panel (the “

18 /Apr

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

April 18, 2022 Shanghai, China——Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered into a Master Collaboration Agreement (Agreement) with AstraZeneca (LSE/STO/Nasd

13 /Apr

Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System

Xiamen, China April 13, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Beckman Coulter Life Sciences, a global leader in life sciences lab automation and innovation, announce

05 /May Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA
20 /Apr Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
18 /Apr AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
13 /Apr Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System

more 

08 /Apr

AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China

Xiamen, China - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13), an innovative, commercial-stage, biopharmaceutical co

15 /Mar

China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)

Xiamen, China, March 15, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that China’s National Medical Products Administration (NMPA) recently granted Approval to A

14 /Mar

Visit AmoyDx at AACR Annual Meeting 2022 in Louisiana, USA

AmoyDx is excited to be back in New Orleans, Louisiana, USA in April for American Association for Cancer Research (AACR) Annual Meeting 2022. Please plan to join us at booth 1265 from 10 - 13 April, 2022 and we look forward to seeing you in New Orleans.

24 /Feb

Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am

08 /Apr AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China
15 /Mar China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)
14 /Mar Visit AmoyDx at AACR Annual Meeting 2022 in Louisiana, USA
24 /Feb Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

more 

24 /Feb

29 /Jan

14 /Jan

10 /Dec

24 /Feb AmoyDx Collaborates with Pierre Fabre to Develop Companion Diagnostics for China Market
29 /Jan AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
14 /Jan AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
10 /Dec AmoyDx Distributors Annual Meeting 2021

more 

Better life with AmoyDx

Better life with AmoyDx

AmoyDx won the Second Prize of National Scientific and Technological Progress Award

Better life with AmoyDx

ABOUT AMOYDX

Latest News

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Amoy Diagnostics and Roche Jointly Announce Strategic Partnership

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System

AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China

China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)

Visit AmoyDx at AACR Annual Meeting 2022 in Louisiana, USA

Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

New Products

New Products

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

ESMO Asia

AMP

Stock Info

Better life with AmoyDx

Better life with AmoyDx

AmoyDx won the Second Prize of National Scientific and Technological Progress Award

Better life with AmoyDx

ABOUT AMOYDX

Latest News

AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation

Amoy Diagnostics and Roche Jointly Announce Strategic Partnership

MHLW Approves AmoyDx® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek® (Entrectinib) in Japan

Visit AmoyDx at IASLC 2022 World Conference on Lung Cancer in Vienna, Austria from August 6 – 9,

Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA

Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan

Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System

AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China

China's NMPA Granted Approval to AmoyDx® PD-L1 Expression Detection Kit (IHC)

Visit AmoyDx at AACR Annual Meeting 2022 in Louisiana, USA

Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

New Products

New Products

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

Pan Lung Cancer PCR Panel

HRD Focus Panel

HANDLE Classic NGS Panel

BRCA Pro Panel

ESMO Asia

AMP

Stock Info

MHLW Approves AmoyDx^® Pan Lung Cancer PCR Panel as Companion Diagnostic for Rozlytrek^® (Entrectinib) in Japan

Filing Notice for a Manufacturing and Marketing Application for AmoyDx^® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer

China's NMPA Granted Approval to AmoyDx^® PD-L1 Expression Detection Kit (IHC)